Please ensure Javascript is enabled for purposes of website accessibility

Drug Deals Require Cash

By Brian Orelli, PhD - Updated Apr 5, 2017 at 8:04PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pharmaceutical companies find out how nice it is not to have to take out loans.

It's nice to have cash. It allows you to buy things like unusually cheap stocks or companies of which you already own 56%. Unfortunately for Roche, not having cash seems to be making it hard to close its $45 billion deal for Genentech (NYSE:DNA). The availability of credit just isn't what it used to be.

Not everyone is having problems closing their deals, though. Eli Lilly (NYSE:LLY) didn't need much of a loan to close its $6.5 billion purchase of ImClone Systems. It had $6.1 billion in cash and short-term investments at the end last quarter, so it needed only a relatively small loan of $2 billion to $3 billion to get the job done.

Cash is king and it's allowing companies to swoop in and get some good deals.

Johnson & Johnson (NYSE:JNJ) went on a bit of a spending spree over the last couple of weeks. On Monday it bought Mentor for a little over $1 billon and picked up much smaller Omrix Biopharmaceuticals last week. Even with those purchase, the company still has plenty of cash left.

Check out these players in the pharmaceutical field.

 

Cash and short-term investments (billions)

Pfizer (NYSE:PFE)

$26.0

Wyeth (NYSE:WYE)

$14.2

Johnson & Johnson

$14.8

GlaxoSmithKline (NYSE:GSK)

$9.9

Novartis (NYSE:NVS)

$8.1

Source: Capital IQ, a division of Standard & Poor's. As of the quarter ending September 2008.

That's a lot of cash that could be deployed. To put it in perspective, the companies above could pay double the current market caps for Amylin Pharmaceuticals, Elan, Onyx Pharmaceuticals, Genzyme, Seattle Genetics, and PDL Biopharma, and still have plenty left over as a cushion.

In Warren Buffett-like fashion, pharmaceutical companies have been hoarding cash -- patiently waiting for good prices. And it looks like that time has arrived. There are a lot of drug developers that have been knocked down even though the prospects of their pipelines haven't changed very much.

Enjoy your holiday shopping, pharma.

Johnson & Johnson, Eli Lilly, Glaxo, and Pfizer are all Motley Fool Income Investor recommendations. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is also an Inside Value pick and the Fool owns shares of it. Omrix Biopharmaceuticals is a Rule Breakers pick. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$304.61 (0.53%) $1.59
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$170.67 (0.29%) $0.49
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.95 (0.34%) $0.17
Novartis AG Stock Quote
Novartis AG
NVS
$87.43 (0.32%) $0.28
GSK Stock Quote
GSK
GSK
$38.30 (-4.32%) $-1.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.